Literature DB >> 18702912

Rhinitis medicamentosa: therapeutic effect of diode laser inferior turbinate reduction on nasal obstruction and decongestant abuse.

Philipp P Caffier1, Katja Frieler, Hans Scherer, Benedikt Sedlmaier, Onder Göktas.   

Abstract

BACKGROUND: The purpose of this study was to evaluate long-term outcomes of an outpatient-based diode laser inferior turbinate reduction (ITR) in therapy-refractory rhinitis medicamentosa (RM).
METHODS: In a prospective clinical investigation, 42 consecutive RM patients underwent videoendoscopic ITR with a diode laser after topical anesthetic preparation. Intra- and perioperative details were recorded including the occurrence of bleeding, crusting, pain, or discomfort. Treatment efficiency was assessed by follow-ups 1 and 6 weeks as well as 6 and 12 months after surgery. Subjective pre- and posttherapeutic nasal airflow (NA) and patient satisfaction were rated on visual analog scales (VASs). Assessment of the long-term objective clinical effectiveness was based on rhinomanometry, IT photodocumentation, and the recurrent need for decongestants.
RESULTS: Preoperative addiction to decongestants lasted 5 +/- 2 years (mean +/- SD). There was no major bleeding requiring nasal packing, and there were no other perioperative complications. Postoperative edema disappeared within the 1st week and crusting within 6 weeks after surgery. VAS was characterized by very low values for intraoperative pain and discomfort and high postoperative patient satisfaction. After 6 months, NA data revealed a significant improvement of subjective VAS and objective rhinomanometry (250.4-413.9 cm3/s inspiration at 150 Pa). A total of 88% of patients managed to successfully stop decongestant abuse after 6 months (74% after 1 year).
CONCLUSION: In therapy-refractory RM, outpatient diode laser ITR of hyperplastic IT represents a highly effective, safe, and well-tolerated treatment option that provides long-lasting recovery by markedly improving NA and stopping addiction to nasal decongestants.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18702912     DOI: 10.2500/ajr.2008.22.3199

Source DB:  PubMed          Journal:  Am J Rhinol        ISSN: 1050-6586


  8 in total

1.  Low level laser therapy for patients with cervical disk hernia.

Authors:  Hiroshi Takahashi; Ikuko Okuni; Nobuyuki Ushigome; Takashi Harada; Hiroshi Tsuruoka; Toshio Ohshiro; Masayuki Sekiguchi; Yoshiro Musya
Journal:  Laser Ther       Date:  2012-09-30

2.  Diode laser treatment of hypertrophic inferior turbinates and evaluation of the results with acoustic rhinometry.

Authors:  Hamdi Cakli; Cemal Cingi; Emine Güven; Melek Kezban Gurbuz; Ercan Kaya
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-02-19       Impact factor: 2.503

3.  Effect of laser treatment on olfactory dysfunction.

Authors:  Onder Göktas; Larissa Lau; Franca Fleiner
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2011-12-20

4.  Physiology and pathophysiology of respiratory mucosa of the nose and the paranasal sinuses.

Authors:  Achim G Beule
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2011-04-27

5.  Surgery of the turbinates and "empty nose" syndrome.

Authors:  Marc Oliver Scheithauer
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2011-04-27

6.  Rhinitis medicamentosa: a nationwide survey of Canadian otolaryngologists.

Authors:  James Fowler; Christopher J Chin; Emad Massoud
Journal:  J Otolaryngol Head Neck Surg       Date:  2019-12-09

7.  Comparison of efficacy of potassium titanyl phosphate laser & diode laser in the management of inferior turbinate hypertrophy: A randomized controlled trial.

Authors:  Subhashini Puducherry Ravichandran; Karthikeyan Ramasamy; Pradipta Kumar Parida; Arun Alexander; Sivaraman Ganesan; Sunil Kumar Saxena
Journal:  Indian J Med Res       Date:  2020-06       Impact factor: 2.375

8.  Diode Laser Reduction of Symptomatic Inferior Turbinate Hypertrophy.

Authors:  Nain Bahadur Mahato; Deepak Regmi; Meera Bista
Journal:  JNMA J Nepal Med Assoc       Date:  2018 Nov-Dec       Impact factor: 0.406

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.